sacm1lb Antibody

How do I select the appropriate SACM1L/sacm1lb antibody for my experimental system?

When selecting a SACM1L/sacm1lb antibody, consider several critical factors:

• Species reactivity: Verify documented reactivity with your experimental model. For instance, antibodies like ABIN6264916 show reactivity with human, mouse, and rat samples, while others may be limited to specific species .

• Application compatibility: Match the antibody to your experimental technique. For example:

  Application	Recommended Dilution	Example Catalog Numbers
  Western Blot (WB)	1:500-1:2000	13033-1-AP, ab172402
  Immunohistochemistry (IHC)	1:20-1:200	13033-1-AP, ABIN7163155
  Immunofluorescence (IF)	1:50-1:500	13033-1-AP, ABIN949071
  Immunoprecipitation (IP)	0.5-4.0 μg per 1-3 mg lysate	13033-1-AP

• Epitope consideration: Select antibodies targeting conserved regions for cross-species studies. For zebrafish-specific studies, consider the homology between human SACM1L and zebrafish sacm1lb .

• Validation evidence: Review published literature citing the antibody in your application of interest. Sources mention 15 publications for WB, 6 for IF, and 1 for IP applications with certain antibodies .

What validation steps should I perform before using a SACM1L/sacm1lb antibody in critical experiments?

A robust validation protocol should include:

• Positive and negative controls:

  • Positive controls: Use tissues/cells with known expression (e.g., human kidney tissue, A549 cells, mouse kidney tissue for SACM1L) .

  • Negative controls: Include SACM1L knockout cells as demonstrated in publications using CRISPR-Cas9 system .

• Molecular weight verification: Confirm detection at the expected molecular weight (60-67 kDa for human SACM1L) .

• Subcellular localization patterns: Verify expected cytoplasmic and membrane patterns (ER and Golgi apparatus) .

• Knockdown/knockout validation: The gold standard involves comparing antibody signals in wild-type versus SACM1L-depleted samples. Published studies demonstrate this approach using CRISPR-Cas9 to generate SACM1L knockout HeLa cell lines .

• Cross-reactivity assessment: Test on tissues/cells from multiple species if planning cross-species studies.

How should I design experiments to study SACM1L/sacm1lb's role in membrane trafficking and phosphoinositide regulation?

A comprehensive experimental design should include:

• Subcellular fractionation and colocalization studies:

  • Use IF/ICC with organelle markers for ER and Golgi (dilution 1:50-1:500) .

  • Combine with phosphoinositide probes to track PI(4)P levels.

• Functional assays:

  • Implement phosphatase activity assays to measure PI(4)P to PI conversion.

  • Monitor PI(4)P levels in different cellular compartments using specific biosensors.

• Protein-protein interaction studies:

  • Perform immunoprecipitation (IP) using 0.5-4.0 μg antibody per 1.0-3.0 mg protein lysate .

  • Consider proximity ligation assays to detect interactions with trafficking machinery.

• Loss-of-function approaches:

  • Generate knockout/knockdown models using CRISPR-Cas9 or siRNA.

  • Use antibodies to confirm successful depletion (1:500-1:2000 dilution for WB) .

• Rescue experiments:

  • Reintroduce wild-type or phosphatase-dead mutants of SACM1L.

  • Use antibodies to confirm expression levels of rescue constructs.

What are the key considerations when studying SACM1L/sacm1lb's role in autophagy pathways?

Research from Liu et al. demonstrates that SACM1L plays a critical role in xenophagy (pathogen-targeted autophagy). When designing experiments:

• Autophagosome maturation assays:

  • Track LC3-I to LC3-II conversion in the presence/absence of SACM1L using WB (1:500-1:2000 dilution) .

  • Implement tandem mCherry-GFP-LC3 reporters to distinguish immature autophagosomes (mCherry+GFP+) from acidified autolysosomes (mCherry+GFP-) .

• Bacterial infection models:

  • Use Salmonella infection models as established by Liu et al.

  • Monitor bacterial targeting by key xenophagy markers (LC3, NDP52, SQSTM1) .

• Control experiments:

  • Compare basal and non-selective autophagy to xenophagy (pathogen-specific autophagy).

  • Include lysosomal function assays (LysoTracker, DQ-green BSA) .

• Quantitative microscopy:

  • Implement time-dependent confocal imaging of infected cells.

  • Track degradation of autophagy markers using antibody detection at optimal dilutions (1:20-1:200 for IHC) .

Data table from published research:

Note: Data approximated from Liu et al., showing delayed clearance of autophagy markers in SACM1L KO cells .

How can I optimize immunofluorescence protocols for detecting SACM1L/sacm1lb in subcellular compartments?

For optimal IF/ICC detection of SACM1L/sacm1lb:

• Fixation and permeabilization:

  • Test both PFA (4%) and methanol fixation methods.

  • Use 0.1-0.2% Triton X-100 or 0.1% saponin for permeabilization.

• Antibody dilution optimization:

  • Start with the recommended dilution range (1:50-1:500) .

  • Perform titration experiments to determine optimal signal-to-noise ratio.

• Antigen retrieval considerations:

  • For tissue sections, use TE buffer pH 9.0 or citrate buffer pH 6.0 as suggested for SACM1L antibodies .

• Colocalization markers:

  • Include established ER markers (calnexin, PDI) and Golgi markers (GM130, TGN46).

  • Consider phosphoinositide probes to correlate with enzymatic function.

• Signal amplification:

  • For low-abundance detection, implement tyramide signal amplification.

  • Consider super-resolution microscopy techniques for precise localization.

• Common pitfalls to avoid:

  • Day-to-day variations in antibody staining may occur; ensure consistent protocols .

  • Include proper controls in every experiment, including knockout/knockdown samples .

How can I address non-specific binding issues with SACM1L/sacm1lb antibodies?

When encountering non-specific binding:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers).

  • Increase blocking time (1-2 hours at room temperature or overnight at 4°C).

• Antibody dilution adjustment:

  • Further dilute primary antibody beyond recommended range if background is high.

  • Reduce incubation time or temperature.

• Validation in knockout/knockdown systems:

  • Use SACM1L knockout cells as negative controls, as demonstrated in published studies .

  • Implement siRNA knockdown if knockout cells are unavailable.

• Pre-adsorption controls:

  • Pre-incubate antibody with immunizing peptide/protein when available.

  • For SACM1L, some antibodies are raised against fusion protein Ag3682 .

• Alternative antibody selection:

  • Consider antibodies targeting different epitopes (N-terminal, C-terminal, or internal regions).

  • Compare polyclonal versus monoclonal options for specificity.

Why might I observe discrepancies in molecular weight detection when using SACM1L/sacm1lb antibodies?

Molecular weight variations can occur due to:

• Post-translational modifications:

  • SACM1L has a calculated molecular weight of 67 kDa but is often observed at 60-67 kDa .

  • Phosphorylation states may alter migration patterns.

• Species-specific differences:

  • Human SACM1L versus zebrafish sacm1lb may show different molecular weights.

  • Verify expected size for your specific model organism.

• Isoform detection:

  • Alternative splicing may generate different isoforms.

  • Antibody epitope location determines which isoforms are detected.

• Technical factors:

  • SDS-PAGE conditions (percentage, buffer system) affect migration.

  • Sample preparation (reducing conditions, denaturation temperature) influences observed size.

• Validation approaches:

  • Run positive control samples with known expression (e.g., human kidney tissue) .

  • Include size markers and molecular weight standards.

  • Compare with recombinant protein standards when available.

What strategies can help resolve contradictory results between different detection methods for SACM1L/sacm1lb?

When faced with contradictory results:

• Methodological validation:

  • Verify each technique independently with established controls.

  • Ensure antibodies are validated for each specific application (WB, IF, IHC).

• Cross-validation approach:

  • Use multiple antibodies targeting different epitopes of SACM1L/sacm1lb.

  • Compare results from antibody-dependent and antibody-independent methods.

• Experimental conditions assessment:

  • From Liu et al.'s research, SACM1L function appears time-dependent; ensure consistent timing in experiments .

  • Document all experimental variables including fixation, permeabilization, and buffer compositions.

• Statistical analysis:

  • Implement adequate biological and technical replicates (minimum n=3).

  • Use appropriate statistical tests to determine significance of observed differences.

• Complementary techniques:

  • For protein-protein interactions, combine IP data with proximity ligation assays.

  • For localization studies, complement IF with subcellular fractionation and WB.

How can I effectively use SACM1L/sacm1lb antibodies to investigate its role in pathogen defense mechanisms?

Based on Liu et al.'s findings on SACM1L's role in xenophagy:

• Infection models:

  • Establish bacterial infection protocols (e.g., Salmonella Typhimurium).

  • Monitor bacterial replication using CFU assays or bioluminescence .

• Xenophagy pathway investigation:

  • Track LC3, NDP52, SQSTM1, and ubiquitin recruitment to bacteria using antibodies at optimal dilutions .

  • Implement time-course studies (0.5h, 1h, 2h post-infection) to capture dynamic processes.

• Phosphoinositide dynamics analysis:

  • Monitor PI(4)P accumulation on bacterial-containing autophagosomes.

  • Study the relationship between PI(4)P levels and bacterial effector recruitment .

• Lysosomal fusion assessment:

  • Use LAMP1 markers and lysosomal enzyme probes (pepstatin A, MagicRed, DQ-BSA).

  • Quantify the percentage of bacteria reaching mature, degradative compartments .

• Experimental design considerations:

  • Include both WT and SACM1L knockout/knockdown conditions.

  • Perform rescue experiments with wild-type and phosphatase-dead SACM1L.

Results from published research:

Note: Data derived from Liu et al., demonstrating SACM1L's role in xenophagy completion .

What are the recommended approaches for studying interactions between SACM1L/sacm1lb and other phosphoinositide regulatory enzymes?

To investigate SACM1L/sacm1lb interactions with other phosphoinositide regulators:

• Co-immunoprecipitation studies:

  • Use SACM1L antibodies at 0.5-4.0 μg per 1.0-3.0 mg protein lysate .

  • Include appropriate controls (IgG control, input control).

  • Validate results with reverse IP using antibodies against interacting partners.

• Proximity-based interaction assays:

  • Implement BioID or TurboID proximity labeling.

  • Use FRET or BiFC to detect direct protein-protein interactions.

• Functional relationship studies:

  • Generate single and double knockouts/knockdowns of SACM1L and interacting partners.

  • Measure phosphoinositide levels using specific biosensors or biochemical assays.

• Structural and domain analysis:

  • Identify critical interaction domains through truncation mutants.

  • Use antibodies against specific domains to potentially disrupt interactions.

• In vivo validation:

  • For zebrafish studies, use morpholino knockdown or CRISPR-Cas9 approaches.

  • Combine with rescue experiments expressing specific domains or mutants.

How can I design experiments to study the temporal and spatial dynamics of SACM1L/sacm1lb during cellular responses?

For studying dynamic SACM1L/sacm1lb processes:

• Live cell imaging approaches:

  • Generate fluorescently tagged SACM1L constructs.

  • Use antibody-based detection in fixed cells at defined timepoints.

• Stimulus-response experiments:

  • Monitor SACM1L localization following cellular stresses (starvation, infection).

  • Track phosphoinositide dynamics in parallel using specific biosensors.

• Quantitative microscopy:

  • Implement FRAP (Fluorescence Recovery After Photobleaching) to measure protein mobility.

  • Use structured illumination or super-resolution microscopy for precise localization.

• Biochemical fractionation:

  • Perform subcellular fractionation at defined timepoints.

  • Use Western blotting with SACM1L antibodies (1:500-1:2000) to track redistribution .

• Mathematical modeling:

  • Incorporate experimental data into models of phosphoinositide dynamics.

  • Predict consequences of SACM1L perturbation on membrane identity and trafficking.

• Experimental design considerations:

  • Controls for antibody specificity must be included at each timepoint.

  • Single stain controls should be run every time you perform flow cytometry experiments to account for variations in antibody staining, fluorophore stability, and instrument stability .

What methodologies are effective for investigating SACM1L/sacm1lb's role in disease models?

For disease-related SACM1L research:

• Neurodegenerative disease models:

  • SACM1L is expressed in human brain tissue, making it relevant for neurological studies .

  • Use antibodies for IHC in brain tissue (1:20-1:200 dilution) .

• Infectious disease studies:

  • Build on established Salmonella infection models .

  • Explore SACM1L's role in defense against other intracellular pathogens.

• Cancer research applications:

  • Analyze SACM1L expression and localization in tumor vs. normal tissues.

  • Investigate connections between membrane trafficking defects and cancer progression.

• Technical considerations:

  • For tissue-based studies, optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) .

  • Include proper negative controls (SACM1L-depleted tissues or cells).

  • Validate antibody specificity in each specific disease model.

How can I use sacm1lb antibodies effectively in zebrafish developmental studies?

For zebrafish-specific research:

• Embryonic expression analysis:

  • Perform whole-mount immunohistochemistry at various developmental stages.

  • Test cross-reactivity of mammalian SACM1L antibodies with zebrafish sacm1lb.

• Knockdown/knockout approaches:

  • Generate sacm1lb morphants or CRISPR mutants.

  • Use antibodies to confirm protein depletion.

• Tissue-specific studies:

  • Referenced in RNA splicing research, sacm1lb intron 16 has been used as a control intron in zebrafish .

  • Focus on tissues with known expression (based on RNA data).

• Phosphoinositide dynamics:

  • Compare PI(4)P regulation between mammalian and zebrafish models.

  • Investigate conservation of function across vertebrate species.

• Technical considerations:

  • Optimize fixation protocols for zebrafish embryos (typically 4% PFA).

  • Test multiple antibodies targeting different epitopes to identify those recognizing zebrafish sacm1lb.

  • Include wild-type and sacm1lb-depleted samples as controls.